Incidence of TRAEs*
| Event, n (%) | Advanced RCC N=49 | |
| Any grade | Grade 3–4 | |
| TRAEs | 48 (98.0) | 19 (38.8) |
| TRAEs with an incidence ≥20% (any grade) or more than one patient at grade 3–4 | ||
| Fatigue | 37 (75.5) | 2 (4.1) |
| Pyrexia | 24 (49.0) | 1 (2.0) |
| Chills | 24 (49.0) | 0 |
| Influenza-like illness | 24 (49.0) | 0 |
| Pruritus | 24 (49.0) | 0 |
| Nausea | 23 (46.9) | 0 |
| Rash | 19 (38.8) | 0 |
| Decreased appetite | 19 (38.8) | 1 (2.0) |
| Arthralgia | 17 (34.7) | 1 (2.0) |
| Edema peripheral | 16 (32.7) | 0 |
| Diarrhea | 15 (30.6) | 0 |
| Vomiting | 15 (30.6) | 0 |
| Myalgia | 14 (28.6) | 1 (2.0) |
| Headache | 11 (22.4) | 0 |
| Hypothyroidism | 11 (22.4) | 0 |
| Rash maculopapular | 11 (22.4) | 0 |
| Cough | 10 (20.4) | 0 |
| Hypotension | 10 (20.4) | 2 (4.1) |
| Syncope | 4 (8.2) | 4 (8.2) |
| Increased lipase | 3 (6.1) | 3 (6.1) |
| Hyponatremia | 2 (4.1) | 2 (4.1) |
Data cut-off: January 8, 2021.
*The incidence of TRAEs from any component of the study treatment is shown. Patients are only counted once under each preferred term using the highest grade; some patients may have experienced more than one event.
RCC, renal cell carcinoma; TRAE, treatment-related adverse event.